Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of TAK-475 alone or with ezetimibe versus ezetimibe in primary dyslipidemia
2005-002315-25Phase 3Completed
- Sponsor
- Takeda
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary dyslipidaemia comparing TAK-475 monotherapy, Ezetimibe monotherapy and TAK-475 + ezetimibe combination therapy (3 arms). Primary endpoints: Primary efficacy endpoint, LDL-C reduction: TAK-475 versus ezetimibe and 1 more. Started Aug 2005; status: completed.
02
Drugs
lapaquistatezetimibe
03
Conditions
primary dyslipidaemia
Beyond the preview
Go deeper on 2005-002315-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002315-25.